Key result
Rapid AS progression plus high CT-derived ECV is linked to ~6.2-fold higher adverse event rates.
Why the study?
Is accelerated aortic stenosis progression associated with greater CT-derived extracellular volume fraction and worse clinical outcomes in patients with classical high-gradient severe aortic stenosis?
Cohort (n=134)
Is accelerated aortic stenosis progression associated with greater CT-derived extracellular volume fraction and worse clinical outcomes in patients with classical high-gradient severe aortic stenosis?
Faster aortic stenosis progression is independently associated with greater diffuse myocardial fibrosis on cardiac CT, and their combination identifies severe AS patients at substantially higher risk of adverse clinical events.
Answers are grounded in this paper and cite their sources.
CT-ECV may flag fibrosis in rapid AS progression; leaves open its value for pre-TAVI risk stratification.
Rapid progression of aortic stenosis (AS) is associated with adverse outcomes, yet the myocardial changes accompanying faster progression remain incompletely characterized. We evaluated the association between the rate of AS progression and myocardial fibrosis assessed by computed tomography (CT)-derived extracellular volume fraction (ECV), and the impact on clinical outcomes. We studied 134 patients with classical high-gradient severe AS who underwent pre-transcatheter aortic valve implantation cardiac CT with a delayed dual-energy acquisition for ECV quantification and had at least two echocardiograms ≥ 6 months apart. Progression was defined as the annualized change in peak aortic jet velocity. Rapid progression was defined as an increase > 0.30 m/s/year. Patients were followed for a composite of cardiovascular hospitalization, urgent aortic valve replacement, or death. ECV correlated with progression rate (Spearman ρ = 0.33, p < 0.001). In multivariable linear regression, faster progression remained independently associated with ECV (β = 2.52, p = 0.001). Rapid progressors had higher ECV than slow progressors (31.5% vs. 28.3%, p < 0.001). Over a median follow-up of 16.2 months, 36 patients (26.9%) reached the composite outcome. Patients with both rapid progression and high ECV had an event rate of 69 versus 11 per 100 patient-years in those without (adjusted HR 6.22, 95% CI 3.13-12.32). Faster AS progression is independently associated with greater diffuse myocardial fibrosis, irrespective of stenosis severity, and their combination identified patients at higher risk of adverse events. These findings suggest that AS progression rate and myocardial tissue characterization carry complementary prognostic information in severe AS.
No takes yet. Share an insight, caveat, or question.
Lobo et al. (2026) conducted a cohort in Classical high-gradient severe aortic stenosis (n=134). Rapid aortic stenosis progression (>0.30 m/s/year) combined with high CT-derived extracellular volume fraction (ECV) vs. Patients without both rapid progression and high ECV was evaluated on Composite of cardiovascular hospitalization, urgent aortic valve replacement, or death (HR 6.22, 95% CI 3.13-12.32). Rapid aortic stenosis progression combined with high CT-derived ECV was associated with a higher rate of adverse clinical events (69 vs 11 per 100 patient-years; adjusted HR 6.22, 95% CI 3.13-12.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: